Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma Purpose: Response of solid malignancies to therapy is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback